Additionally, the 36-month beta value for SCPH is 0.31. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SCPH is 34.26M and currently, short sellers hold a 16.54% ratio of that float. The average trading volume of SCPH on March 28, 2025 was 396.62K shares.
SCPH) stock’s latest price update
scPharmaceuticals Inc (NASDAQ: SCPH)’s stock price has dropped by -3.95 in relation to previous closing price of 3.04. Nevertheless, the company has seen a loss of -2.67% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-19 that scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo – Investor Relations John Tucker – Chief Executive Officer Steve Parsons – Senior Vice President of Commercial Rachael Nokes – Chief Financial Officer Conference Call Participants Stacy Ku – TD Cowen Glen Santangelo – Jefferies Roanna Ruiz – Leerink Partners Douglas Tsao – H.C. Wainwright Naz Rahman – Maxim Group Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call.
SCPH’s Market Performance
scPharmaceuticals Inc (SCPH) has experienced a -2.67% fall in stock performance for the past week, with a -9.88% drop in the past month, and a -13.61% drop in the past quarter. The volatility ratio for the week is 5.88%, and the volatility levels for the past 30 days are at 6.24% for SCPH. The simple moving average for the past 20 days is -4.17% for SCPH’s stock, with a -27.12% simple moving average for the past 200 days.
Analysts’ Opinion of SCPH
Many brokerage firms have already submitted their reports for SCPH stocks, with Craig Hallum repeating the rating for SCPH by listing it as a “Buy.” The predicted price for SCPH in the upcoming period, according to Craig Hallum is $20 based on the research report published on September 07, 2023 of the previous year 2023.
Cowen, on the other hand, stated in their research note that they expect to see SCPH reach a price target of $25. The rating they have provided for SCPH stocks is “Outperform” according to the report published on December 01st, 2022.
Jefferies gave a rating of “Buy” to SCPH, setting the target price at $14 in the report published on October 21st of the previous year.
SCPH Trading at -9.53% from the 50-Day Moving Average
After a stumble in the market that brought SCPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.32% of loss for the given period.
Volatility was left at 6.24%, however, over the last 30 days, the volatility rate increased by 5.88%, as shares sank -10.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.00% lower at present.
During the last 5 trading sessions, SCPH fell by -2.00%, which changed the moving average for the period of 200-days by -28.64% in comparison to the 20-day moving average, which settled at $3.05. In addition, scPharmaceuticals Inc saw -17.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SCPH starting from ORBIMED ADVISORS LLC, who purchase 500,000 shares at the price of $4.00 back on Aug 13 ’24. After this action, ORBIMED ADVISORS LLC now owns 5,806,670 shares of scPharmaceuticals Inc, valued at $2,000,000 using the latest closing price.
Stock Fundamentals for SCPH
Current profitability levels for the company are sitting at:
- -1.78 for the present operating margin
- 0.69 for the gross margin
The net margin for scPharmaceuticals Inc stands at -2.34. The total capital return value is set at -0.7. Equity return is now at value -336.97, with -84.31 for asset returns.
Based on scPharmaceuticals Inc (SCPH), the company’s capital structure generated 0.8 points at debt to capital in total, while cash flow to debt ratio is standing at -1.34. The debt to equity ratio resting at 3.96. The interest coverage ratio of the stock is -8.56.
Currently, EBITDA for the company is -77.56 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 3.41. The receivables turnover for the company is 3.1for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.12.
Conclusion
In conclusion, scPharmaceuticals Inc (SCPH) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
